Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Zebisch, A, Pichler, A, Pfeilstocker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Geissler, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R. J Hematol Oncol. 2016, 9:39.

Bcl-2 proteins in development, health, and disease of the hematopoietic system.

Kollek, M, MГјller, A, Egle, A, Erlacher, M. FEBS J. 2016, 283(15):2779-2810.

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic HematopoiesisMasters of Survival and Clonality?.

Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A. Oncotarget. 2016.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

Greil, R, Obrtlíková, P, Smolej, L, Kozák, T, Steurer, M, Andel, J, Burgstaller, S, Mikušková, E, Gercheva, L, Nösslinger, T, Papajík, T, Ladická, M, Girschikofsky, M, Hrubiško, M, Jäger, U, Fridrik, M, Pecherstorfer, M, Králiková, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, Flochová, E, Palášthy, S, Stehlíková, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A. Lancet Haematol. 2016, 3(7):e317-e329.

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.

Rinnerthaler, G, Hackl, H, Gampenrieder, SP, Hamacher, F, Hufnagl, C, Hauser-Kronberger, C, Zehentmayr, F, Fastner, G, Sedlmayer, F, Mlineritsch, B, Greil, R. Int J Mol Sci. 2016, 17(2).

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Huemer, F, Dejaco, M, Grabmer, C, Melchardt, T, Neureiter, D, Mayer, G, Egle, A, Greil, R, Weiss, L. Wien Klin Wochenschr. 2016.

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis -Masters of Survival and Clonality?.

Pleyer, L, Valent, P, Greil, R. INT J MOL SCI. 2016, 17(7): 1009.

An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide?+?dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).

Leleu, X, Terpos, E, Sanz, RG, Cooney, J, O”Gorman, P, Minarik, J, Greil, R, Williams, C, Gray, D, Szabo, Z. AM J HEMATOL. 2016, 91(8): 806-811.

Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.

Steiner, M, Harrer, A, Himly, M. Front Pharmacol. 2016, 7:171.

CD44: More than a mere stem cell marker.

Morath, I, Hartmann, TN, Orian-Rousseau, V. Int J Biochem Cell Biol. 2016.